Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.77 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.77 |
| ▸ | SSTR5 | P35346 | 6/20 | 0.43 |
| ▸ | SSTR2 | P30874 | 4/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 4/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | TERF2 | Q15554 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | KLK7 | P49862 | 1/20 | 0.40 |
| ▸ | LDHB | P07195 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Polymyxin B Nonapeptide SCHEMBL25547777 | 1.00 | KDM1A (0.77) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| Polymyxin B Nonapeptide SCHEMBL17882149 | 1.00 | KDM1A (0.77) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| Polymyxin B Nonapeptide SCHEMBL20108926 | 1.00 | KDM1A (0.77) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| Polymyxin B Nonapeptide SCHEMBL29358904 | 1.00 | KDM1A (0.77) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| Polymyxin B Nonapeptide SCHEMBL19386845 | 1.00 | KDM1A (0.77) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| SCHEMBL25547809 | 0.95 | KDM1A (0.71) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| SCHEMBL19545532 | 0.94 | KDM1A (0.70) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| SCHEMBL18165213 | 0.93 | KDM1A (0.73) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| SCHEMBL29360076 | 0.93 | KDM1A (0.73) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| SCHEMBL19532558 | 0.92 | KDM1A (0.76) | KDM1ARCOR1SSTR5SSTR2SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024003042-A1 | NOVEL COMBINATIONS OF SESQUITERPENE ALCOHOLS, POLYMYXINS AND NISIN COMPOUNDS AS ANTIMICOBIAL AND/OR ANTIFUNGAL COMPOUNDS | BREAKTHROUGH BIOTECH DRIFT APS (DK) | 2024-01-04 | — | — | WO | claimed |
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2023-05-11 | — | — | US | claimed |
| CN-115298198-A | Novel compounds and compositions for targeted therapy of kidney-related cancers | 上海盟科药业股份有限公司 | 2022-11-04 | — | — | CN | claimed |
| US-11293024-B2 | Antisense antibacterial compounds and methods | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-04-05 | — | — | US | claimed |
| CN-215642596-U | Circuit with ultralow power consumption and power-on reset and power-off reset functions | 江苏稻源科技集团有限公司 | 2022-01-25 | — | — | CN | claimed |
| US-20260103491-A1 | ARYL SUBSTITUTED POLYMYXIN DERIVATIVES | SPERO THERAPEUTICS INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12595251-B2 | Amidines and amidine analogs for the treatment of bacterial infections and potentiation antibiotics | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-12528837-B2 | Aryl substituted polymyxin derivatives | SPERO THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4652183-A1 | PEPTIDE-DRUG CONJUGATES FOR TARGETED THERAPY OF RENAL DISEASES | Shanghai MicuRx Pharmaceutical Co., Ltd. (CN) | 2025-11-26 | — | — | EP | disclosed |
| US-20250302846-A1 | ANTIBIOTIC COMPOSITION AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2025-10-02 | — | — | US | disclosed |
| US-20250305023-A1 | MEASUREMENT OF PERMEATION OF SMALL MOLECULES INTO GRAM NEGATIVE BACTERIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2025-10-02 | — | — | US | disclosed |
| US-20250271744-A1 | LIGHT SOURCE APPARATUS AND PROJECTOR | SEIKO EPSON CORPORATION (JP) | 2025-08-28 | — | — | US | disclosed |
| EP-3969461-A1 | HOMODIMERIC TOBRAMYCIN ADJUVANT REPURPOSES NOVOBIOCIN AS AN EFFECTIVE ANTIBACTERIAL AGENT AGAINST GRAM-NEGATIVE BACTERIA | University of Manitoba (CA) | 2022-03-23 | — | — | EP | disclosed |
| US-20220072098-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | LAUREN SCIENCES LLC | 2022-03-10 | — | — | US | disclosed |
| WO-2022046997-A1 | BAMA-BINDING AGENTS AND METHODS OF USE THEREOF | NGM BIOPHARMACEUTICALS, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| EP-3116897-B1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS INC (US) | 2022-03-02 | — | — | EP | disclosed |
| EP-3955929-A1 | NEW PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | Université de Liège (BE) | 2022-02-23 | — | — | EP | disclosed |
| EP-3942038-A1 | MODULATORS OF TDP-43 | Alteron Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-215642596-U | Circuit with ultralow power consumption and power-on reset and power-off reset functions | 江苏稻源科技集团有限公司 | 2022-01-25 | — | — | CN | disclosed |
| US-10449230-B2 | Polymyxin derived cell penetrating scaffolds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072098-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | GFRA2, GFRA1, NGF | KDM1A 4135/4885RCOR1 3937/4885SSTR5 1479/4885 |
| US-12528837-B2 | Aryl substituted polymyxin derivatives | PTMS, PNISR, BCAT2 | KDM1A 1242/4885RCOR1 3294/4885SSTR5 1737/4885 |
| US-20260103491-A1 | ARYL SUBSTITUTED POLYMYXIN DERIVATIVES | PTMS, FPR1, BCAT2 | KDM1A 1156/4885RCOR1 3053/4885SSTR5 1169/4885 |
| US-10449230-B2 | Polymyxin derived cell penetrating scaffolds | SLC47A2, SLC47A1, KPNB1 | KDM1A 4605/4885RCOR1 4872/4885SSTR5 3114/4885 |
| US-12595251-B2 | Amidines and amidine analogs for the treatment of bacterial infections and potentiation antibiotics | CLIC1, CBR3, CBR1 | KDM1A 4519/4885RCOR1 1417/4885SSTR5 200/4885 |
| US-11293024-B2 | Antisense antibacterial compounds and methods | RNGTT, DCLRE1B, POLRMT | KDM1A 4714/4885RCOR1 3953/4885SSTR5 3339/4885 |
| US-20250302846-A1 | ANTIBIOTIC COMPOSITION AND METHODS OF USE THEREOF | SPOUT1, CUTA, MYD88 | KDM1A 4228/4885RCOR1 4790/4885SSTR5 3660/4885 |
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | GLS, ATP6V1B1, KRAS | KDM1A 3592/4885RCOR1 4682/4885SSTR5 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.